Zentalis Pharmaceuticals
ZNTL
ZNTL
117 hedge funds and large institutions have $64.6M invested in Zentalis Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 44 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
117
Holders Change
-15
Holders Change %
-11.36%
% of All Funds
1.57%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
22
Increased
34
Reduced
44
Closed
37
Calls
–
Puts
$73K
Net Calls
-$73K
Net Calls Change
+$84K
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
$1.13M |
| 2 |
Renaissance Technologies
New York
|
$1.77M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
$1.32M |
| 4 |
Two Sigma Investments
New York
|
$1.27M |
| 5 |
TCM
Tybourne Capital Management
Hong Kong
|
$1.71M |
Top Sellers
| 1 |
BlackRock
New York
|
$2.02M |
| 2 |
State Street
Boston,
Massachusetts
|
$315K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
$717K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
$46.1K |
| 5 |
DC
Decheng Capital
Menlo Park,
California
|
$1.54M |
